Headache and Migraine

 
Atogepant Safe, Effective in Treatment-Resistant Episodic Migraine: Daily Dose
March 04, 2024

Your daily dose of the clinical news you may have missed.

Atogepant Safe and Effective in Treatment-Resistant Episodic Migraine: ELEVATE Phase 3b Trial
February 27, 2024

Atogepant once daily reduced mean monthly headache days in adults for whom up to 4 classes of oral migraine preventives were ineffective.

Migraine-Related Stigma Impacts Quality of Life: Daily Dose
February 05, 2024

Your daily dose of the clinical news you may have missed.

The Most Effective Medications for Acute Migraines: Patient Perspectives
January 26, 2024

Which medications are most effective for acute migraine management? A recent study assessed which ones appeared to work best based on reported patient experience.

Migraine-related Stigma is Common and Impacts Level of Disability, Quality of Life
January 25, 2024

Reports of migraine-related stigma were common in a recent population-based study, with nearly one-third reporting the experience often/very often.

Older Adults with New Onset Migraine 3 Times More Likely to Have Motor Vehicle Accident
January 05, 2024

Older adults with a history of migraine, in contrast, were at no greater risk of an automotive crash than those without prevalent migraine, according to new study results.

Migraine Management during the Holidays: How to Help Patients Identify, Manage Triggers
December 22, 2023

Common triggers, such as stress, travel, and disrupted routines, can impact patients with migraine this holiday season. Practical strategies and short-term preventive measures to help, here.

Daily Dose: Nerivio Neuromodulation Device for Migraine
December 14, 2023

Your daily dose of the clinical news you may have missed.

Nerivio Neuromodulation Device Maintains Efficacy, Safety at 1 Year of Consistent Use for Migraine
December 07, 2023

Among study participants with migraine, investigators observed consistent and persistent device efficacy for pain relief, pain freedom, and functional disability freedom.

Ubrogepant Taken During Migraine Prodrome Reduces Headache Severity: Phase 3 Clinical Trial
December 07, 2023

Ubrogepant 100 mg taken during the migraine prodrome significantly reduced onset of moderate or severe headache for 24 hours after study-drug dose.